UTI Healthcare Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Growthvine rating: 4/5 — ranked #16 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹331.96 (as of 2026-10-01) |
|---|
| AUM | ₹1,444 Cr |
|---|
| Expense ratio | 1.82% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Kamal Gada |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| 5-year annualised return | 14.14% |
|---|
| Sharpe ratio | 1.08 |
|---|
| Standard deviation | 15.92% |
|---|
| Max drawdown | −33.91% |
|---|
| Alpha | 0.83 |
|---|
| Beta | 0.95 |
|---|
Over 5 years, captured 95.0% of NIFTY Pharma's upside and 86.1% of its downside.
Market cap allocation
| Large cap | 20.4% |
|---|
| Mid cap | 35.4% |
|---|
| Small cap | 44.3% |
|---|
Concentration
| Top 5 holdings | 26.5% |
|---|
| Top 10 holdings | 42.3% |
|---|
| Total holdings | 43 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 8.3%
- Divis Laboratories Ltd. — 6.2%
- NET CURRENT ASSETS — 5.7%
- Ajanta Pharma Ltd. — 4.7%
- Gland Pharma Limited — 3.7%
- Dr. Reddys Laboratories Ltd. — 3.6%
- Alkem Laboratories Limited — 3.3%
- Apollo Hospitals Enterprises Ltd. — 3.3%
- Max Healthcare Institute Limited — 3.1%
- Lupin Ltd — 3.1%
Top sectors
- Pharma & Biotech — 67.9%
- Healthcare — 25.0%
- Cash — 5.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 16.9% | Q1 (Top) | #9 of 76 |
| 2025 | −3.1% | Q3 | #45 of 69 |
| 2024 | 42.9% | Q1 (Top) | #4 of 58 |
| 2023 | 38.2% | Q2 | #21 of 48 |
| 2022 | −12.3% | Q4 (Bottom) | #40 of 46 |